FIELD: biotechnology; medicine.
SUBSTANCE: disclosed are antisense modified oligonucleotides, compositions and methods for inhibiting expression of mRNA and protein factor 11. Disclosed antisense oligonucleotides can be used to inhibit the formation of blood clots or clots associated with pathological changes in vascular walls. Also disclosed are methods of treating or preventing thromboembolic complications in an individual in need thereof, particularly deep vein thrombosis, pulmonary embolism, myocardial infarction and stroke.
EFFECT: inhibition of factor 11 mediated by the disclosed antisense oligonucleotides is safer and does not have a canceling effect.
68 cl, 169 tbl, 47 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR MODULATION OF C90RF72 EXPRESSION | 2014 |
|
RU2748426C2 |
| MODULATION OF PREKALLIKREIN (PKK) EXPRESSION | 2014 |
|
RU2712559C2 |
| COMPOUND FOR MODULATION OF C9ORF72 GENE EXPRESSION AND USE THEREOF | 2013 |
|
RU2730677C2 |
| COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF ANGIOPOIETIN-LIKE PROTEIN 3 | 2015 |
|
RU2734658C2 |
| FACTOR 11 EXPRESSION MODULATION | 2009 |
|
RU2535964C2 |
| COMPOSITIONS FOR MODULATING TAU PROTEIN EXPRESSION | 2014 |
|
RU2735551C2 |
| METHODS AND COMPOSITIONS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2013 |
|
RU2748495C2 |
| COMPOSITIONS FOR MODULATING EXPRESSION OF TAU PROTEIN | 2014 |
|
RU2823361C1 |
| COMPOSITIONS AND METHODS FOR MODULATION OF HBV AND TTR EXPRESSION | 2014 |
|
RU2782034C2 |
| MODULATION OF HUNTINGTIN EXPRESSION | 2010 |
|
RU2751847C2 |
